论文部分内容阅读
近日,希腊研究人员在欧洲心脏病学会2006年心衰会议上指出,研究结果表明充血性心衰患者应用重组红细胞生成素治疗可显著改善左心室(LV)的舒张和收缩功能。来自于希腊雅典Attikon大学医学院的心脏科主任、高级研究员Dimitrios Kremastinos博士及其同事在研究中对治疗药物与左心室功能指标是否存在关联性进行了检测研究。研究人员共征集26例充血性心衰疾病患者并以2:1的比例随机分为二组进行试验。一组17例患者被给予1.5mcg/kg剂量的Darbepoetin-α(Aranesp)治疗;另一组9人每20天给予一次安慰剂对照治疗,试验时间3个月。根据受试者左心室的舒张和收缩功能、运动负荷和神经激素活性的基线水平变化进行疗效评估。
Recently, the Greek researchers at the European Society of Cardiology in heart failure in 2006 meeting pointed out that the results show that patients with congestive heart failure using recombinant erythropoietin can significantly improve left ventricular (LV) diastolic and systolic function. Dimitrios Kremastinos, Ph.D., director of cardiology and senior fellow at the Attikon University School of Medicine in Athens, Greece, and colleagues examined the association of treatment medications with left ventricular function in the study. Researchers collected a total of 26 patients with congestive heart failure and 2: 1 ratio were randomly divided into two groups for testing. One group of 17 patients was treated with 1.5 mcg / kg of Darbepoetin-α (Aranesp); the other 9 were given placebo-controlled every 20 days for 3 months. Efficacy was assessed based on changes in left ventricular diastolic and systolic function, exercise load, and baseline levels of neurohormonal activity.